鳞状细胞肺癌的基因组学。
Genomics of squamous cell lung cancer.
机构信息
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63021, USA.
出版信息
Oncologist. 2013 Jun;18(6):707-16. doi: 10.1634/theoncologist.2013-0063. Epub 2013 May 31.
Abstract
Approximately 30% of patients with non-small cell lung cancer have the squamous cell carcinoma (SQCC) histological subtype. Although targeted therapies have improved outcomes in patients with adenocarcinoma, no agents are currently approved specifically for use in SQCC. The Cancer Genome Atlas (TCGA) recently published the results of comprehensive genomic analyses of tumor samples from 178 patients with SQCC of the lung. In this review, we briefly discuss key molecular aberrations reported by TCGA and other investigators and their potential therapeutic implications. Carefully designed preclinical and clinical studies based on these large-scale genomic analyses are critical to improve the outcomes of patients with SQCC of lung in the near future.
摘要
大约 30%的非小细胞肺癌患者具有鳞状细胞癌（SQCC）组织学亚型。尽管针对腺癌患者的靶向治疗已经改善了其预后，但目前尚无专门用于 SQCC 的药物。癌症基因组图谱（TCGA）最近公布了 178 例肺 SQCC 肿瘤样本的综合基因组分析结果。在这篇综述中，我们简要讨论了 TCGA 和其他研究人员报告的关键分子异常及其潜在的治疗意义。基于这些大规模基因组分析精心设计的临床前和临床试验对于改善肺 SQCC 患者的近期预后至关重要。
相似文献
1
Genomics of squamous cell lung cancer.鳞状细胞肺癌的基因组学。
Oncologist. 2013 Jun;18(6):707-16. doi: 10.1634/theoncologist.2013-0063. Epub 2013 May 31.
2
Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).端粒相关基因和端粒长链非编码 RNA 是肺鳞状细胞癌（LUSC）的生物标志物候选物。
Exp Mol Pathol. 2020 Feb;112:104354. doi: 10.1016/j.yexmp.2019.104354. Epub 2019 Dec 16.
3
Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.综合基因组分析鉴定 BRF2 为肺鳞癌中一个新的谱系特异性癌基因。
PLoS Med. 2010 Jul 27;7(7):e1000315. doi: 10.1371/journal.pmed.1000315.
4
Personalized therapy on the horizon for squamous cell carcinoma of the lung.个体化治疗即将开启肺癌鳞癌治疗新纪元。
Lung Cancer. 2013 Jun;80(3):249-55. doi: 10.1016/j.lungcan.2013.02.015. Epub 2013 Mar 13.
5
Multiplatform-based molecular subtypes of non-small-cell lung cancer.基于多平台的非小细胞肺癌分子亚型
Oncogene. 2017 Mar;36(10):1384-1393. doi: 10.1038/onc.2016.303. Epub 2016 Oct 24.
6
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.肺鳞状细胞癌独特的代谢表型定义了对糖酵解抑制的选择性脆弱性。
Nat Commun. 2017 May 26;8:15503. doi: 10.1038/ncomms15503.
7
Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.肺癌亚型在基因组和表观基因组上的差异景观凸显了肿瘤发展过程中不同致癌途径的选择。
PLoS One. 2012;7(5):e37775. doi: 10.1371/journal.pone.0037775. Epub 2012 May 21.
8
Genomic landscape of squamous cell carcinoma of the lung.肺鳞状细胞癌的基因组图谱
Am Soc Clin Oncol Educ Book. 2013:348-53. doi: 10.14694/EdBook_AM.2013.33.348.
9
Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.中国女性不吸烟非腺癌非小细胞肺癌中驱动基因的表达谱分析。
Clin Lung Cancer. 2020 Sep;21(5):e355-e362. doi: 10.1016/j.cllc.2020.02.005. Epub 2020 Feb 10.
10
Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.亚洲晚期非小细胞肺癌应用循环肿瘤 DNA 进行基因组分析的临床应用
Clin Lung Cancer. 2018 Sep;19(5):e601-e608. doi: 10.1016/j.cllc.2018.04.022. Epub 2018 May 7.
引用本文的文献
1
Molecular and immune characterization of Chinese early-stage non-squamous non-small cell lung cancer: a multi-omics cohort study.中国早期非鳞状非小细胞肺癌的分子与免疫特征：一项多组学队列研究
Transl Lung Cancer Res. 2024 Apr 29;13(4):763-784. doi: 10.21037/tlcr-23-800. Epub 2024 Apr 25.
2
Heterogeneous pattern of gene expression driven by mutation is involved in the construction of a prognosis model of lung squamous cell carcinoma.由突变驱动的基因表达异质性模式参与了肺鳞状细胞癌预后模型的构建。
Front Oncol. 2023 Mar 23;13:916568. doi: 10.3389/fonc.2023.916568. eCollection 2023.
3
Brief Report: Prognostic Relevance of 3q Amplification in Squamous Cell Carcinoma of the Lung.简短报告：3q扩增在肺鳞状细胞癌中的预后相关性
JTO Clin Res Rep. 2023 Feb 28;4(4):100486. doi: 10.1016/j.jtocrr.2023.100486. eCollection 2023 Apr.
4
Molecular Pathology of Lung Cancer.肺癌的分子病理学
Cold Spring Harb Perspect Med. 2022 Mar 1;12(3):a037812. doi: 10.1101/cshperspect.a037812.
5
Partial EMT in Squamous Cell Carcinoma: A Snapshot.部分 EMT 在鳞状细胞癌中的表现：快照。
Int J Biol Sci. 2021 Jul 13;17(12):3036-3047. doi: 10.7150/ijbs.61566. eCollection 2021.
6
Downregulation of miRNA-126-3p is associated with progression of and poor prognosis for lung squamous cell carcinoma.miRNA-126-3p 的下调与肺鳞状细胞癌的进展和不良预后相关。
FEBS Open Bio. 2020 Aug;10(8):1624-1641. doi: 10.1002/2211-5463.12920. Epub 2020 Jul 14.
7
ZWINT is the next potential target for lung cancer therapy.ZWINT 是肺癌治疗的下一个潜在靶点。
J Cancer Res Clin Oncol. 2019 Mar;145(3):661-673. doi: 10.1007/s00432-018-2823-1. Epub 2019 Jan 14.
8
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.肺癌：分子特征、克隆异质性与进化以及癌症干细胞
Cancers (Basel). 2018 Jul 27;10(8):248. doi: 10.3390/cancers10080248.
9
Expression ratio of the TGFβ-inducible gene MYO10 is prognostic for overall survival of squamous cell lung cancer patients and predicts chemotherapy response.TGFβ 诱导基因 MYO10 的表达比值对鳞状细胞肺癌患者的总生存期具有预后价值，并可预测化疗反应。
Sci Rep. 2018 Jun 22;8(1):9517. doi: 10.1038/s41598-018-27912-1.
10
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.表皮生长因子受体-酪氨酸激酶抑制剂对携带EGFR突变的肺鳞癌的疗效：一项多中心研究及已发表报告的汇总分析。
Oncotarget. 2017 Jul 25;8(30):49680-49688. doi: 10.18632/oncotarget.17915.
本文引用的文献
1
Cancer statistics, 2013.癌症统计数据，2013 年。
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
2
MDM2, MDMX and p53 in oncogenesis and cancer therapy.MDM2、MDMX 和 p53 在肿瘤发生和癌症治疗中的作用。
Nat Rev Cancer. 2013 Feb;13(2):83-96. doi: 10.1038/nrc3430. Epub 2013 Jan 10.
3
Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412.抑制 Ephrin B3 介导的生存信号有助于非小细胞肺癌细胞在接受电离辐射和 PKC 412 联合治疗后增加细胞死亡反应。
Cell Death Dis. 2013 Jan 10;4(1):e454. doi: 10.1038/cddis.2012.188.
4
Targeting epigenetic readers in cancer.针对癌症中的表观遗传阅读器
N Engl J Med. 2012 Nov 1;367(18):1764-5. doi: 10.1056/NEJMc1211175.
5
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.肺鳞癌：新兴生物学、争议与靶向治疗的前景。
Lancet Oncol. 2012 Oct;13(10):e418-26. doi: 10.1016/S1470-2045(12)70291-7.
6
Comprehensive genomic characterization of squamous cell lung cancers.全面基因组特征分析鳞状细胞肺癌
Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9.
7
The roles and therapeutic potentials of Ephs and ephrins in lung cancer.Eph 受体及其配体 Ephrins 在肺癌中的作用和治疗潜力。
Exp Cell Res. 2013 Jan 15;319(2):152-9. doi: 10.1016/j.yexcr.2012.08.005. Epub 2012 Aug 31.
8
High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer.FoxP1 高表达与非小细胞肺癌患者的生存改善相关。
Am J Clin Pathol. 2012 Aug;138(2):230-5. doi: 10.1309/AJCPDHQFNYJZ01YG.
9
[Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].[表皮生长因子受体酪氨酸激酶抑制剂疗效与晚期肺鳞状细胞癌中EGFR突变的相关性]
Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):323-8.
10
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.基于组织学和吸烟状况，鉴定非小细胞肺癌患者亚组中富集的驱动基因改变。
PLoS One. 2012;7(6):e40109. doi: 10.1371/journal.pone.0040109. Epub 2012 Jun 29.
Zotero 插件